Prophylaxis of venous thromboembolism: analysis of cost effectiveness.
The rapidly expanding literature regarding prevention of venous thromboembolism is confusing and contradictory, but, when analysed in the aggregate, the collective experience permits a judgment about the relative efficacy of different prophylactic regimens in specific patient populations, who vary in the risk factors predisposing them to thromboembolism. The dollar cost of the several approaches to prevention and their consequences should also be a matter of concern. Efficacy and dollar cost together determine cost effectiveness, which provides a practical guide to selection of the prophylactic approach appropriate to an individual patient.
D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003911:Dextrans / Q000008:administration & dosage / Q000627:therapeutic use; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D011655:Pulmonary Embolism / Q000517:prevention & control; D012306:Risk; D013923:Thromboembolism / Q000191:economics / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000191:economics / Q000517:prevention & control*
D003911:Dextrans; D006493:Heparin; D001241:Aspirin